Showing results (1-10 of 83) with videos related to
Sort By:
Pageof 9
Expert Opinion on Investigational Drugs|November 18, 2021
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyondAlessandro Rizzo, Angela Dalia RicciClinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2026
Unlocking New Possibilities: Dual Immune Blockade in Brain Metastases from Rare TumorsAngela Dalia Ricci, Alessandro RizzoExpert Opinion on Investigational Drugs|August 25, 2021
PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?Alessandro Rizzo, Angela Dalia RicciInternational Journal of Molecular Sciences|October 14, 2022
Challenges and Future Trends of Hepatocellular Carcinoma ImmunotherapyAlessandro Rizzo, Angela Dalia RicciMedicina (Kaunas, Lithuania)|December 24, 2021
Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?Angela Dalia Ricci, Alessandro RizzoCancer Treatment and Research Communications|April 2, 2021
IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?Alessandro Rizzo, Angela Dalia Ricci, Giovanni BrandiCancer Control : Journal of the Moffitt Cancer Center|August 19, 2020
Immunotherapy in Biliary Tract Cancer: Worthy of a Second LookAngela Dalia Ricci, Alessandro Rizzo, Giovanni BrandiExpert Review of Gastroenterology & Hepatology|November 20, 2020
Recent advances of immunotherapy for biliary tract cancerAlessandro Rizzo, Angela Dalia Ricci, Giovanni BrandiCancers|February 4, 2021
PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract CancerAlessandro Rizzo, Angela Dalia Ricci, Giovanni BrandiExpert Opinion on Investigational Drugs|March 1, 2021
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancerAlessandro Rizzo, Angela Dalia Ricci, Giovanni BrandiPageof 9